Interrogating open issues in cancer precision medicine with patient-derived xenografts

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Nature Reviews. Cancer

• Publication date

  2017-01-20

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/nrc.2016.140PMID 28104906
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Faculty of 1000 evaluation for Circulating tumor cells and circulating tumor DNA: challenges and opportunities on the path to clinical utility.

  2017cited by this paper
• Combined inhibition of DDR1 and Notch signaling is a therapeutic strategy for KRAS-driven lung adenocarcinoma

  2016cited by this paper
• Patient-derived Mammosphere and Xenograft Tumour Initiation Correlates with Progression to Metastasis

  2016cited by this paper
• Abstract PR01: Ductal pancreatic cancer modeling and drug screening using human pluripotent stem cell and patient-derived tumor organoids

  2016cited by this paper
• Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer.

  2016cited by this paper
• In Vivo Genetic Screens of Patient-Derived Tumors Revealed Unexpected Frailty of the Transformed Phenotype.

  2016cited by this paper
• Metastatic colonization by circulating tumour cells

  2016cited by this paper
• Evaluation of Alternative In Vivo Drug Screening Methodology: A Single Mouse Analysis.

  2016cited by this paper
• HER2 expression identifies dynamic functional states within circulating breast cancer cells

  2016cited by this paper
• Application of Sequencing, Liquid Biopsies, and Patient-Derived Xenografts for Personalized Medicine in Melanoma.

  2016cited by this paper
• The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice.

  2016cited by this paper
• A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors

  2016cited by this paper
• Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq

  2016cited by this paper
• A Place To Be

  2016cited by this paper
• A Three-Dimensional Organoid Culture System Derived from Human Glioblastomas Recapitulates the Hypoxic Gradients and Cancer Stem Cell Heterogeneity of Tumors Found In Vivo.

  2016cited by this paper
• Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial.

  2016cited by this paper
• Challenging the Cancer Molecular Stratification Dogma: Intratumoral Heterogeneity Undermines Consensus Molecular Subtypes and Potential Diagnostic Value in Colorectal Cancer

  2016cited by this paper
• BRAFV600E Kinase Domain Duplication Identified in Therapy-Refractory Melanoma Patient-Derived Xenografts

  2016cited by this paper
• In Vivo Functional Platform Targeting Patient-Derived Xenografts Identifies WDR5-Myc Association as a Critical Determinant of Pancreatic Cancer.

  2016cited by this paper
• A Biobank of Breast Cancer Explants with Preserved Intra-tumor Heterogeneity to Screen Anticancer Compounds

  2016cited by this paper
• Abstract IA20: Challenges, opportunities, and lessons learned in the bench-to-bedside translation of xenopatient studies

  2016cited by this paper
• Mechanisms of Therapy Resistance in Patient-Derived Xenograft Models of BRCA1-Deficient Breast Cancer.

  2016cited by this paper
• In Vivo 31P magnetic resonance spectroscopic imaging (MRSI) for metabolic profiling of human breast cancer xenografts

  2015cited by this paper
• The isolation and characterization of CTC subsets related to breast cancer dormancy

  2015cited by this paper
• Multifocal clonal evolution characterized using circulating tumour DNA in a case of metastatic breast cancer

  2015cited by this paper
• Abstract 659: Sustained inhibition of HER3 and EGFR is necessary to induce regression of HER2-amplified gastrointestinal carcinomas

  2015cited by this paper
• Prospective derivation of a living organoid biobank of colorectal cancer patients.

  2015cited by this paper
• Preclinical mouse cancer models: a maze of opportunities and challenges.

  2015cited by this paper
• Evaluating patient-derived colorectal cancer xenografts as preclinical models by comparison with patient clinical data.

  2015cited by this paper
• Maintaining Tumor Heterogeneity in Patient-Derived Tumor Xenografts.

  2015cited by this paper
• Analysis of circulating tumor cells derived from advanced gastric cancer

  2015cited by this paper
• Establishment and characterization of a cell line from human circulating colon cancer cells.

  2015cited by this paper
• Circulating and disseminated tumor cells from breast cancer patient-derived xenograft-bearing mice as a novel model to study metastasis

  2015cited by this paper
• Patient-derived orthotopic xenografts: better mimic of metastasis than subcutaneous xenografts

  2015cited by this paper
• Stromal contribution to the colorectal cancer transcriptome

  2015cited by this paper
• Intra- and inter-tumor heterogeneity in a vemurafenib-resistant melanoma patient and derived xenografts

  2015cited by this paper
• Single-cell analysis reveals a stem-cell program in human metastatic breast cancer cells

  2015cited by this paper
• Stromal gene expression defines poor-prognosis subtypes in colorectal cancer

  2015cited by this paper
• Chemokine-Targeted Mouse Models of Human Primary and Metastatic Colorectal Cancer

  2015cited by this paper
• Prognostic and functional importance of the engraftment-associated genes in the patient-derived xenograft models of triple-negative breast cancers

  2015cited by this paper
• Delineation of MGMT Hypermethylation as a Biomarker for Veliparib-Mediated Temozolomide-Sensitizing Therapy of Glioblastoma.

  2015cited by this paper
• Circulating Tumor Cells and Circulating Tumor DNA: Challenges and Opportunities on the Path to Clinical Utility

  2015cited by this paper
• HER2 activating mutations are targets for colorectal cancer treatment.

  2015cited by this paper
• The Genomic Landscape of Response to EGFR Blockade in Colorectal Cancer

  2015cited by this paper
• Microenvironmental hCAP-18/LL-37 promotes pancreatic ductal adenocarcinoma by activating its cancer stem cell compartment

  2015cited by this paper
• Proteomic profiling of patient‐derived glioblastoma xenografts identifies a subset with activated EGFR: implications for drug development

  2015cited by this paper
• Clinical Utility of Patient-Derived Xenografts to Determine Biomarkers of Prognosis and Map Resistance Pathways in EGFR-Mutant Lung Adenocarcinoma.

  2015cited by this paper
• A retrospective observational study of clinicopathological features of KRAS, NRAS, BRAF and PIK3CA mutations in Japanese patients with metastatic colorectal cancer

  2015cited by this paper
• Tumorigenesis: it takes a village

  2015cited by this paper
• IGF2 is an actionable target that identifies a distinct subpopulation of colorectal cancer patients with marginal response to anti-EGFR therapies

  2015cited by this paper
• A first-in-human phase I trial of LY2780301, a dual p70 S6 kinase and Akt Inhibitor, in patients with advanced or metastatic cancer

  2015cited by this paper
• Anti-estrogen Resistance in Human Breast Tumors Is Driven by JAG1-NOTCH4-Dependent Cancer Stem Cell Activity

  2015cited by this paper
• Effect of cellular senescence on the growth of HER2-positive breast cancers.

  2015cited by this paper
• Concise Review: Humanized Models of Tumor Immunology in the 21st Century: Convergence of Cancer Research and Tissue Engineering

  2015cited by this paper
• Patient-derived xenograft models for pancreatic adenocarcinoma demonstrate retention of tumor morphology through incorporation of murine stromal elements.

  2015cited by this paper
• High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response

  2015cited by this paper
• Preserved genetic diversity in organoids cultured from biopsies of human colorectal cancer metastases

  2015cited by this paper
• Generation of Prostate Cancer Patient Derived Xenograft Models from Circulating Tumor Cells.

  2015cited by this paper
• Construction of orthotopic xenograft mouse models for human pancreatic cancer.

  2015cited by this paper
• Organoid models of human and mouse ductal pancreatic cancer.

  2015cited by this paper
• The risk of newly diagnosed cancer in patients with rheumatoid arthritis by TNF inhibitor use: a nationwide cohort study

  2015cited by this paper
• XactMice: humanizing mouse bone marrow enables microenvironment reconstitution in a patient-derived xenograft model of head and neck cancer

  2015cited by this paper
• Studying clonal dynamics in response to cancer therapy using high-complexity barcoding

  2015cited by this paper
• Development and function of human innate immune cells in a humanized mouse model

  2014cited by this paper
• Inference of tumor evolution during chemotherapy by computational modeling and in situ analysis of genetic and phenotypic cellular diversity.

  2014cited by this paper
• Interplay of choline metabolites and genes in patient-derived breast cancer xenografts

  2014cited by this paper
• Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.

  2014cited by this paper
• Patient-Derived Xenografts from Non–Small Cell Lung Cancer Brain Metastases Are Valuable Translational Platforms for the Development of Personalized Targeted Therapy

  2014cited by this paper
• Patient-derived models of acquired resistance can identify effective drug combinations for cancer

  2014cited by this paper
• Circulating Tumor Cells as a Biomarker of Response to Treatment in Patient-Derived Xenograft Mouse Models of Pancreatic Adenocarcinoma

  2014cited by this paper
• Phase I Expansion and Pharmacodynamic Study of the Oral MEK Inhibitor RO4987655 (CH4987655) in Selected Patients with Advanced Cancer with RAS–RAF Mutations

  2014cited by this paper
• Imaging preclinical tumour models: improving translational power

  2014cited by this paper
• Circulating Tumor Cells: A Multifunctional Biomarker

  2014cited by this paper
• Patient-derived xenografts for individualized care in advanced sarcoma

  2014cited by this paper
• Biology, detection, and clinical implications of circulating tumor cells

  2014cited by this paper
• Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3.

  2014cited by this paper
• Microenvironment-derived HGF overcomes genetically determined sensitivity to anti-MET drugs.

  2014cited by this paper
• Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma

  2014cited by this paper
• Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets.

  2014cited by this paper
• Dynamics of genomic clones in breast cancer patient xenografts at single-cell resolution

  2014cited by this paper
• Evolution of the cancer stem cell model.

  2014cited by this paper
• Convergent loss of PTEN leads to clinical resistance to a PI3Kα inhibitor

  2014cited by this paper
• Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility

  2014cited by this paper
• Patient-derived xenograft models: an emerging platform for translational cancer research.

  2014cited by this paper
• A Novel Humanized Bone Marrow Niche Xenotransplantation Model Allows Superior Engraftment of Human Normal and Malignant Hematopoietic Cells and Reveals Myelofibrosis-Initiating Cells in the HSC Compartment

  2014cited by this paper
• Establishment of and comparison between orthotopic xenograft and subcutaneous xenograft models of gallbladder carcinoma.

  2014cited by this paper
• The requirement for freshly isolated human colorectal cancer (CRC) cells in isolating CRC stem cells

  2014cited by this paper
• Emergence of Constitutively Active Estrogen Receptor-α Mutations in Pretreated Advanced Estrogen Receptor–Positive Breast Cancer

  2014cited by this paper
• Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer

  2014cited by this paper
• Acquired Resistance to Endocrine Treatments Is Associated with Tumor-Specific Molecular Changes in Patient-Derived Luminal Breast Cancer Xenografts

  2014cited by this paper
• PIK3CA Mutational Status in Circulating Tumor Cells Can Change During Disease Recurrence or Progression in Patients with Breast Cancer

  2014cited by this paper
• Organoid cultures derived from patients with advanced prostate cancer.

  2014cited by this paper
• Challenges in circulating tumour cell research

  2014cited by this paper
• DNA barcoding reveals diverse growth kinetics of human breast tumour subclones in serially passaged xenografts

  2014cited by this paper
• Molecular analysis of circulating tumour cells—biology and biomarkers

  2014cited by this paper
• Intracellular autofluorescence: a biomarker for epithelial cancer stem cells

  2014cited by this paper
• Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy.

  2014cited by this paper
• Trial Watch: Phase II and Phase III attrition rates 2011–2012

  2013cited by this paper
• Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer.

  2013cited by this paper
• Human Regulatory T Cells Do Not Suppress the Antitumor Immunity in the Bone Marrow: A Role for Bone Marrow Stromal Cells in Neutralizing Regulatory T Cells

  2013cited by this paper

• Establishment of a Large‐Scale PDX Library of Head and Neck Cancers for Functional Precision Oncology

  2026cites this paper
• Identification of potentially deleterious mutations in gastric cancer using patient-derived xenograft models

  2026cites this paper
• Patient-derived tumor organoids: advances, applications, and future directions in biomedical research

  2026cites this paper
• Introduction to animal modelling: factors and tools for choosing the optimal model for sarcoma research—a comprehensive literature review

  2026cites this paper
• Bridging the Translational Gap in HNSCC Immunotherapy: From Resistance Mechanisms to High-Fidelity Preclinical Models.

  2026cites this paper
• Harnessing PDX and PDX 2.0: the next-generation paradigm for precision oncology and translational breakthroughs.

  2026cites this paper
• Precision Medicine for Peritoneal Carcinomatosis—Current Advances in Organoid Drug Testing and Clinical Applicability

  2025cites this paper
• Tumor organoids may be more suitable for clinical personalized chemotherapeutic drug screening in lung adenocarcinoma

  2025cites this paper
• Technological advances in clinical individualized medication for cancer therapy: from genes to whole organism.

  2025cites this paper
• Bridging the gap between bench and bedside: Organoid technology in colorectal cancer treatment

  2025cites this paper
• Site-specific ligase-dependent conjugation with ring-opening linker improves safety and stability of HER2-targeting ADCs

  2025influential citation
• Prediction of Patient Drug Response via 3D Bioprinted Gastric Cancer Model Utilized Patient‐Derived Tissue Laden Tissue‐Specific Bioink

  2025cites this paper
• Integrating model systems and genomic insights to decipher mechanisms of cancer metastasis

  2025cites this paper
• A Guide to Breast Cancer Research: An Introduction.

  2025cites this paper
• Boosting human immunology: harnessing the potential of immune organoids

  2025cites this paper
• Advances and Challenges in Human 3D Solid Tumor Models

  2025cites this paper
• Prospects and challenges of ovarian cancer organoids in chemotherapy research (Review)

  2025cites this paper
• Advances in the application of patient-derived xenograft models in acute leukemia resistance

  2025cites this paper
• Comprehensive assessment of computational methods for cancer immunoediting

  2025cites this paper
• Personalized prediction of anticancer potential of non-oncology drugs through learning from genome derived molecular pathways

  2025cites this paper
• Tumor organoids: A review of culture methods, applications in cancer research, precision medicine, and drug development

  2025cites this paper
• The Molecular and Functional Landscape of Resistance to FOLFIRI Chemotherapy in Metastatic Colorectal Cancer

  2025cites this paper
• Co-targeting MERTK and EGFR with a Bispecific Antibody Overcomes Drug Resistance Across Mutations in Exons 19, 20, and 21

  2025cites this paper
• Humanized glioblastoma patient-derived orthotopic xenografts recreate a locally immunosuppressed human immune ecosystem amenable to immunotherapeutic modulation

  2025cites this paper
• Preclinical models of soft tissue sarcomas - generation and applications to enhance translational research.

  2025cites this paper
• Patient-Derived Xenografts of Breast Cancer.

  2025cites this paper
• Establishment and characteristic analysis of a novel patient derived cell line of intrahepatic cholangiocarcinoma

  2025cites this paper
• In vivo intratumoral heterogeneity in a dish: scalable forebrain organoid models of embryonal brain tumors for high‐throughput personalized drug discovery

  2025cites this paper
• Silk Fibroin-Enhanced Peptide Self-Assembled Biomimetic Hydrogel for 3D Cell Proliferation

  2025cites this paper
• Nanomaterials Application for STING Pathway-Based Tumor Immunotherapy

  2025cites this paper
• Clinical Outcomes of Patients With Advanced ALK-Rearranged Lung Squamous Cell Carcinoma Treated With ALK Tyrosine Kinase Inhibitors.

  2025cites this paper
• Establishment of a Chinese library of patient-derived xenografts from gastrointestinal cancers

  2025influential citation
• RANK/RANKL Signaling Pathway in Breast Development and Cancer.

  2025cites this paper
• A pan-cancer, pan-treatment model for predicting drug responses from patient-derived xenografts

  2025cites this paper
• The establishment of organoids and their applications

  2025cites this paper
• Patient-derived xenograft models of gastrointestinal stromal tumors provide a ready-to-use platform for translational research

  2025cites this paper
• RNA methylation of CD47 mediates tumor immunosuppression in EGFR-TKI resistant NSCLC

  2025cites this paper
• Harnessing ferroptosis for precision oncology: challenges and prospects

  2025cites this paper
• Tumor organoid and tumor-on-a-chip equipped next generation precision medicine

  2025cites this paper
• EGF-Upregulated lncRNA ESSENCE Promotes Colorectal Cancer Growth through Stabilizing CAD and Ferroptosis Defense

  2025cites this paper
• A Pan-Cancer, Pan-Treatment (PCPT) Model For Predicting Drug Responses From Patient-Derived Xenografts With Application To Cancer Types With Sparse Training Data

  2025cites this paper
• Results of the phase I/II study and preliminary B cell gene signature of combined inhibition of glutamine metabolism and EGFR in colorectal cancer.

  2025cites this paper
• Impact of Subcutaneous Versus Orthotopic Implantations on Patient-Derived Xenograft Transcriptomic Profiles

  2025cites this paper
• Inhibition of Wnt/β-catenin increases anti-tumor activity by synergizing with sorafenib in hepatocellular carcinoma

  2025cites this paper
• Comparative analysis of patient-derived organoids and patient-derived xenografts as avatar models for predicting response to anti-cancer therapy

  2025cites this paper
• Tumor Microenvironment‐Responsive Nanomedicines for Potentiating Cancer Immunotherapy

  2025cites this paper
• In vivo cancer modeling using mouse models.

  2025cites this paper
• Endometrial diseases: A summary of small experimental animal model†.

  2025cites this paper
• Modeling Glioblastoma with Brain Organoids: New Frontiers in Oncology and Space Research

  2025cites this paper
• Renal capsule patient-derived xenograft model for gastric cancer: establishment and MRI characterization

  2025cites this paper
• Sympathetic axonogenesis promotes adenoid cystic carcinoma progression.

  2025cites this paper
• Steroid hormone receptors, exome sequencing and treatment responsiveness of breast cancer patient-derived xenografts originated in a South American country

  2025cites this paper
• Repurposed AT9283 triggers anti-tumoral effects by targeting MKK3 oncogenic functions in Colorectal Cancer

  2024cites this paper
• Extracellular matrix regulation of cell spheroid invasion in a 3D bioprinted solid tumor-on-a-chip.

  2024cites this paper
• CTC-derived pancreatic cancer models serve as research tools and are suitable for precision medicine approaches

  2024cites this paper
• Genomic profiling of a multi-lineage and multi-passage patient-derived xenograft biobank reflects heterogeneity of ovarian cancer

  2024cites this paper
• Cancer organoids 2.0: modelling the complexity of the tumour immune microenvironment

  2024cites this paper
• OBSERVE: guidelines for the refinement of rodent cancer models

  2024cites this paper
• Leveraging preclinical models of metastatic breast cancer.

  2024cites this paper
• Tumor Cell Stemness and Stromal Cell Features Contribute to Oral Cancer Outcome Disparity in Black Americans

  2024cites this paper
• Gastrointestinal Cancer Patient Derived Organoids at the Frontier of Personalized Medicine and Drug Screening

  2024cites this paper
• Evaluation of Combined Chemotherapy and Genomic-Driven Targeted Therapy in Patient-Derived Xenografts Identifies New Therapeutic Approaches in Squamous Non-Small-Cell Lung Cancer Patients

  2024cites this paper
• The potential of organoids in renal cell carcinoma research

  2024cites this paper
• Representation of genomic intratumor heterogeneity in multi-region non-small cell lung cancer patient-derived xenograft models

  2024cites this paper
• Gastric Cancer Assembloids Derived from Patient‐Derived Xenografts: A Preclinical Model for Therapeutic Drug Screening

  2024cites this paper
• Precision Oncology and Systemic Targeted Therapy in Pseudomyxoma Peritonei

  2024cites this paper
• The use of organoids in creating immune microenvironments and treating gynecological tumors

  2024cites this paper
• Mouse Models for Head and Neck Squamous Cell Carcinoma

  2024cites this paper
• The Transformative Role of 3D Culture Models in Triple-Negative Breast Cancer Research

  2024cites this paper
• Optimization of a method for determination of docetaxel sensitivity using prostate cancer organoids

  2024cites this paper
• Patient-Derived Xenografts: A Valuable Preclinical Model for Drug Development and Biomarker Discovery.

  2024cites this paper
• Challenging the status quo to improve the translational potential of preclinical oncology studies

  2024cites this paper
• Revolutionizing digestive system tumor organoids research: Exploring the potential of tumor organoids

  2024cites this paper
• Microfluidic high-throughput 3D cell culture

  2024cites this paper
• Patient-derived organoids in human cancer: a platform for fundamental research and precision medicine

  2024cites this paper
• The Significance of Xenogenic Models of Malignant Neoplasms In Vivo for Preclinical Studies in Experimental Oncology

  2024cites this paper
• Recent advances in breast cancer cell line research

  2024cites this paper
• Omics-based molecular classifications empowering in precision oncology

  2024cites this paper
• Patient-derived tumor-like cell clusters for personalized chemo- and immunotherapies in non-small cell lung cancer.

  2024cites this paper
• Magnetic resonance imaging-guided intracranial resection of glioblastoma tumors in patient-derived orthotopic xenografts leads to clinically relevant tumor recurrence

  2024cites this paper
• Liensinine sensitizes colorectal cancer cells to oxaliplatin by targeting HIF-1α to inhibit autophagy.

  2024cites this paper
• Simultaneous inhibition of FAK and ROS1 synergistically repressed triple-negative breast cancer by upregulating p53 signalling

  2024cites this paper
• A New Microfluidic Device to Facilitate Functional Precision Medicine Assays.

  2024cites this paper
• Pancreatic cancer environment: from patient-derived models to single-cell omics.

  2024cites this paper
• Humanized mouse models for anti-cancer therapy.

  2024cites this paper
• A Self‐Assembled 3D Model Demonstrates How Stiffness Educates Tumor Cell Phenotypes and Therapy Resistance in Pancreatic Cancer

  2024cites this paper
• Human GM-CSF/IL-3 enhance tumor immune infiltration in humanized HCC patient-derived xenografts

  2024cites this paper
• Human GM-CSF/IL-3 enhance tumor immune infiltration in humanized HCC patient-derived xenografts

  2024cites this paper
• Myeloid Cell Mobilization and Recruitment by Human Mesothelioma in NSG-SGM3 Mice

  2024cites this paper
• PDX models for functional precision oncology and discovery science

  2024cites this paper
• Development of bioengineered 3D patient derived breast cancer organoid model focusing dynamic fibroblast–stem cell reciprocity

  2024cites this paper
• Modeling craniopharyngioma for drug screening reveals a neuronal mechanism for tumor growth.

  2024cites this paper
• Tissue-engineered patient-derived osteosarcoma models dissecting tumour-bone interactions

  2024cites this paper
• Drug screening approaches for small-molecule compounds in cancer-targeted therapy

  2024cites this paper
• Novel strategies to assess cytokine release mediated by chimeric antigen receptor T cells based on the adverse outcome pathway concept

  2024cites this paper
• Ex Vivo Intestinal Organoid Models: Current State-of-the-Art and Challenges in Disease Modelling and Therapeutic Testing for Colorectal Cancer

  2024cites this paper
• Generation of Metastatic Cholangiocarcinoma Patient-Derived Xenograft Models.

  2024cites this paper
• Integrative ensemble modelling of cetuximab sensitivity in colorectal cancer patient-derived xenografts

  2024cites this paper
• Castrate-resistant prostate cancer response to taxane is determined by an HNF1-dependent apoptosis resistance circuit

  2024cites this paper
• Generation, evolution, interfering factors, applications, and challenges of patient-derived xenograft models in immunodeficient mice

  2023cites this paper